Angiotensin-converting-enzyme inhibitors (ACE inhibitors) and angiotensin II receptor blocker (ARB) use in COVID-19 prevention or treatment: A paradox.

Javanmard, Shaghayegh Haghjooy; Heshmat-Ghahdarijani, Kiyan; Vaseghi, Golnaz

Javanmard, Shaghayegh Haghjooy; Heshmat-Ghahdarijani, Kiyan; Vaseghi, Golnaz.

Javanmard SH; Applied Physiology Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran.
Heshmat-Ghahdarijani K; Heart Failure Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran.
Vaseghi G; Isfahan Cardiovascular Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran.

Infect Control Hosp Epidemiol ; 42(1): 118-119, 2021 01.

Article in English | MEDLINE | ID: covidwho-2096303

Subject(s)

Angiotensin Receptor Antagonists; COVID-19; SARS-CoV-2/physiology; Angiotensin Receptor Antagonists/pharmacology; Angiotensin Receptor Antagonists/therapeutic use; Angiotensin-Converting Enzyme 2/metabolism; COVID-19/prevention & control; COVID-19/therapy; COVID-19/virology; Cardiovascular Diseases/drug therapy; Cardiovascular Diseases/metabolism; Humans; Medication Therapy Management; Spike Glycoprotein, Coronavirus/metabolism; Virus Internalization/drug effects

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Angiotensin Receptor Antagonists / SARS-CoV-2 / COVID-19 Limits: Humans Language: English Journal: Infect Control Hosp Epidemiol Journal subject: Communicable Diseases / Nursing / Epidemiology / Hospitals Year: 2021 Document Type: Article Affiliation country: Ice.2020.195

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google